Abstract
The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Keywords: Neuroprotective, Parkinson, genetics
Current Neuropharmacology
Title: Neuroprotective Strategies for Parkinsons Disease
Volume: 2 Issue: 3
Author(s): Ippolita Cantuti-Castelvetri and David G. Standaert
Affiliation:
Keywords: Neuroprotective, Parkinson, genetics
Abstract: The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Export Options
About this article
Cite this article as:
Cantuti-Castelvetri Ippolita and Standaert G. David, Neuroprotective Strategies for Parkinsons Disease, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359585
DOI https://dx.doi.org/10.2174/1570159043359585 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Pharmacological Aspects of (-)-Deprenyl
Current Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology New Classes of AChE Inhibitors with Additional Pharmacological Effects of Interest for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?
Current Neurovascular Research The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine
Current Topics in Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis
Current Drug Targets Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Reviews on Recent Clinical Trials Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein
Current Alzheimer Research Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets